Akèy › Myelom Miltip › Ohio
Etid klinik pou Myelom Miltip nan Ohio
46 etid pou Myelom Miltip ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 104, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07582432A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Cincinnati
- Research Site, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT04973605A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
- ak 4 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06500884A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Cleveland Clinic, Cleveland
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 25, 2026 · NCT07149857Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology, Columbus
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06052826A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Gabrail Cancer Center, Canton
- The Christ Hospital, Cincinnati
- Dayton Physicians Network Urology, Dayton
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Ohio State University, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07393282TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Cincinnati Medical Center, Cincinnati
- Kettering Health, Kettering
- West Chester Hospital, West Chester
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06465316Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Cleveland Clinic, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Oncology Hematology Care, Cincinnati
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- TriHealth Cancer and Blood Institute, Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07555938A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07681596Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
- Gabrail Cancer & Research Center, Canton
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06087653MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- ak 5 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Canton
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OhioHealth O'Bleness Hospital, Athens
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- ak 15 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05651932A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06292780Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Cincinnati
- Research Site, Cleveland
- Research Site, Columbus
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
- The Ohio State University /ID# 271336, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 21, 2026 · NCT06892522A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT07657312A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- The Ohio State University James Cancer Hospital, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Indu and Raj Soin Medical Center, Beavercreek
- Saint Elizabeth Boardman Hospital, Boardman
- Dayton Physicians LLC-Miami Valley South, Centerville
- ak 17 plis
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Cincinnati, Cincinnati
- Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
- Ohio State Medical Center, James Cancer Center, Columbus
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus
Ap rekriteFaz 2
Laj 19 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06974786Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 2, 2026 · NCT05145400A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT07609030Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
Ap rekriteFaz 1
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Oncology Hematology Care, Cincinnati
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT05972135Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Ohio State University James Cancer Hospital, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT03761108A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.